OncoAlert

The OncoAlert 🚨Newsletter Covering September November 14-21, 2024 REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0 Discussing ✅ Goteborg 🇸🇪in #prostatecancer ✅Matching to Clinical trials with TrialGPT💻 ✅PULSAR: ☢️Ultra-fractionated Stereotactive Adaptive RT with CNS 🧠active drugs ✅CHIPOR in #OvarianCancer Adding HIPEC to Cytoreductive surgery improves OS ✅EXENTORCH 🫁in #SCLC: Adding toripalimab to chemo improves PFS and OS ✅TITAN in #ProstateCancer Prof. Dr. Axel S. Merseburger Neeraj Agarwal, MD, FASCO ✅ ICI's effectiveness in Black vs White patients 👨🏻👨🏿 ✅Global Disparities in Cancer Care American Cancer Society Journals ✅OPAR: Partial Irradiation in 5 Fractions Once Daily for Early #BreastCancer Ane Gerda Zahl Eriksson Jarushka Naidoo Nina Sanford Stephen Liu Matteo Lambertini Icro Meattini Stephanie Graff, MD, FACP, FASCO Erika Hamilton, MD Benedikt Westphalen Yüksel ÜRÜN Daniel Castellano #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps--Maléa Biagio Ricciuti Emre Yekeduz Hidehito Horinouchi José Fernando Prado Moura Elisa Agostinetto Elisabetta Bonzano Eric Singhi Bárbara Melão Dr. Joseph McCollom DO Fabio Martinelli Luca Arecco Niklas Klümper

Researchers found that inhibiting the ISR kinase GCN2 in p53-deficient hashtag #ProstateCancer cells disrupts amino acid availability, which is crucial for purine nucleotide synthesis. This disruption is deadly to p53-deficient cells because they cannot initiate the protective cell cycle arrest and senescence that p53 typically triggers.

Day One of #BLADDR24 Presenter:Dr. Petros Grivas Debate: Withholding radical treatment after CR with neoadjuvant treatment: future-talk or not? The concept of withholding radical treatment, such as radical cystectomy (RC) or radiotherapy, for patients with a clinical complete response (cCR) after neoadjuvant or induction systemic therapy is emerging as a potential future approach in bladder cancer management. Radical treatments are associated with significant morbidity and quality of life (QoL) impacts, while a subset of patients show remarkable responses to systemic therapies, raising the possibility of bladder preservation. Evidence suggests that transurethral resection of bladder tumor (TURBT) combined with chemotherapy may yield favorable outcomes in selected patients. For deep responders with negative clinical and molecular findings (e.g., negative ctDNA), the question is whether they could achieve excellent long-term oncology outcomes and maintain their QoL without radical surgery. The future may see systemic therapies, such as immunotherapy and antibody-drug conjugates Ursula Vogl Petros Grivas Fabio Turco Dra. María Natalia Gandur Quiroga Emre Yekeduz Bárbara Melão Niklas Klümper Ignacio Duran Univ. Prof. Dr. Manuela Schmidinger Saeed Dabestani Geraldine PIGNOT Yüksel ÜRÜN Badrinath Konety Maria De Santis Renate Pichler Daniele Raggi Laura Mertens Daan De Maeseneer Verane Achard eva Comperat Peter Hoskin Cédric Lebâcle Laura Mertens Celena Scheede-Bergdahl Bernadett Szabados

The OncoAlert Network along with our partners at @ESSOnews @ESGO_society @CancerCareMASCC & @SIOGorg and our Collaborators @APCCC_Lugano @ABCGlobalAll @kidneycan @GuardConsortium @mybsmo @gu_onc Proudly Announce the first 2/3 of our faculty, more to come very soon. Register for FREE HERE: https://buff.ly/3CChgre @hoperugo 🇺🇸 @ErikaHamilton9 🇺🇸 @Silke_Gillessen 🇨🇭 @GillSharlene 🇨🇦 @DrBetofMDPhD 🇺🇸 @GlopesMd 🇺🇸 @Icro_Meattini 🇮🇹 @DrJNaidoo 🇮🇪 @matteolambe 🇮🇹 @agz_eriksson 🇳🇴 @PGrivasMDPhD 🇺🇸 Roberto Salgado 🇧🇪 @declangmurphy 🇦🇺 @RenuEapen 🇦🇺 @VincentWenxinXu 🇺🇸 Fatima Cardoso 🇵🇹 @HenningWillers 🇺🇸 @E_de_Azambuja 🇧🇪 @kevinpunie 🇧🇪 @EnriqueSoto8 🇺🇸 @NiuSanford 🇺🇸 @CharuAggarwalMD 🇺🇸 @advocatekidneys 🇺🇸 @MelissaLoh21 🇺🇸 @weoncologists 🇺🇸 #OncoAlertAF @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @lungoncdoc @bavilima @realbowtiedoc @Erman_Akkus @DrFMartinelli @Lucarecco @heinrich_kat @niklas_kluemper

Day One of #BLADDR24 Presenter: Dr Gunhild von Amsberg First-line treatment for advanced UCa: balancing between efficacy, safety, patient characteristics and QoL The presentation on first-line treatment for advanced urothelial carcinoma (UCa) highlights the need to balance efficacy, safety, patient characteristics, and quality of life. According to ESMO guidelines, enfortumab vedotin plus pembrolizumab (EV + P) is the preferred first-line therapy for unresectable or metastatic UCa, regardless of platinum eligibility. For patients unable to receive EV + P, alternative treatments include nivolumab with up to six cycles of cisplatin-gemcitabine (for cisplatin-eligible patients) or six cycles of platinum-based chemotherapy (PBCT) followed by avelumab maintenance in non-progressing cases. Single-agent immune checkpoint inhibitors (ICIs) play a limited role in first-line advanced disease and are not routinely recommended. However, access to these treatment options varies significantly across Europe, with many patients still not receiving systemic therapy. Ursula Vogl Petros Grivas Fabio Turco Dra. María Natalia Gandur Quiroga Emre Yekeduz Bárbara Melão Niklas Klümper Ignacio Duran Univ. Prof. Dr. Manuela Schmidinger Saeed Dabestani Geraldine PIGNOT Yüksel ÜRÜN Badrinath Konety Maria De Santis Renate Pichler Daniele Raggi Laura Mertens Daan De Maeseneer Verane Achard eva Comperat Peter Hoskin Cédric Lebâcle Laura Mertens Celena Scheede-Bergdahl Bernadett Szabados

Day One of #BLADDR24 Presenter: Dr Celena Scheede-Bergdahl RC and neobladder Topic: Prehabilitation programme Prehabilitation is a process in cancer care that takes place between diagnosis and the start of acute treatment, focusing on physical and psychological assessments to establish a baseline functional level, identify impairments, and provide interventions to promote overall health. The goal is to reduce the risk and severity of future complications. Patient preferences play a crucial role in designing patient-centered programs, addressing barriers to adherence, and understanding what patients are willing to engage in. Evidence suggests that prehabilitation can lead to lasting changes in physical activity and exercise behaviors, with benefits extending even beyond 12 months. It can be implemented before or during chemotherapy or radiation therapy, with exercise intensity adjusted based on the additional stress of treatment, and monitored using tools like the Borg scale to tailor intensity to the patient's daily condition. Ursula Vogl Petros Grivas Fabio Turco Dra. María Natalia Gandur Quiroga Emre Yekeduz Bárbara Melão Niklas Klümper Ignacio Duran Univ. Prof. Dr. Manuela Schmidinger Saeed Dabestani Geraldine PIGNOT Yüksel ÜRÜN Badrinath Konety Maria De Santis Renate Pichler Daniele Raggi Laura Mertens Daan De Maeseneer Verane Achard eva Comperat Peter Hoskin Cédric Lebâcle Laura Mertens Celena Scheede-Bergdahl Bernadett Szabados

Day One of #BLADDR24 Presenter: Dr Cédric Lebâcle Debate: Are we ready to de-intensify treatment and surveillance in low-grade NMIBC? PRO and CON PRO: The debate on whether we are ready to de-intensify treatment and surveillance in low-grade non-muscle invasive bladder cancer (NMIBC) sees the "pro" side arguing that an adapted de-intensification strategy offers several benefits. These include minimizing the risks and side effects of interventions, reducing patient anxiety, and easing the treatment burden, all while ensuring safe and effective care. From a global perspective, this approach can help decrease unnecessary procedures in low-risk NMIBC patients without compromising cancer control, maintaining oncological outcomes while improving overall patient quality of life. Ursula Vogl Petros Grivas Fabio Turco Dra. María Natalia Gandur Quiroga Emre Yekeduz Bárbara Melão Niklas Klümper Ignacio Duran Univ. Prof. Dr. Manuela Schmidinger Saeed Dabestani Geraldine PIGNOT Yüksel ÜRÜN Badrinath Konety Maria De Santis Renate Pichler Daniele Raggi Laura Mertens Daan De Maeseneer Verane Achard eva Comperat Peter Hoskin Cédric Lebâcle Laura Mertens Celena Scheede-Bergdahl Bernadett Szabados Still time to Register: https://buff.ly/3Z4aEt3

Day One of #BLADDR24 Presenter: Dr Petros Grivas Debate: the role of ctDNA to manage MIBC in the adjuvant setting #BladderCancer Presentation discusses if TOMBOLA is practice changing, and more data is needed, particularly in identifying patients who benefit from adjuvant therapy and the predictive role it may play. Serial circulating tumor DNA (ctDNA) monitoring could help stratify risk and prognosis, but it remains unclear if this will impact outcomes. While frequent ctDNA testing could offer insights, it brings challenges in terms of time, logistics, and cost. There may also be other prognostic biomarkers linked to ctDNA clearance. The results from the NIAGARA phase 3 perioperative trial are anticipated and could potentially shift the treatment paradigm. Ursula Vogl Petros Grivas Fabio Turco Dra. María Natalia Gandur Quiroga Emre Yekeduz Bárbara Melão Niklas Klümper Ignacio Duran Univ. Prof. Dr. Manuela Schmidinger Saeed Dabestani Geraldine PIGNOT Yüksel ÜRÜN Verane Achard Eva Comperat Daan De Maeseneer Maria De Santis Kilian Gust Peter Hoskin Badrinath Konety Cedric Lebâcle Laura Mertens Renate Pichler Daniele Raggi Celena Scheede-Bergdahl Bernadett Szabados

Day One of hashtag#BLADDR24 Presenter: Dr. Petros Grivas High-risk BCG-unresponsive NMIBC: are we ready to delay/avoid RC? The presentation on high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) explores various treatment options, including radical cystectomy (RC), pelvic lymph node dissection (PLND), and urinary diversion. FDA-approved therapies for this condition include nadofaragene, ALT803 combined with BCG, and pembrolizumab, while other treatments like gemcitabine-docetaxel and single-agent intravesical chemotherapy are not yet FDA-approved. The presentation also highlights emerging therapies, such as TAR 200, CG0070, and EG70, which could offer new options in the near future. The key challenge is determining the best approach for each patient, as there is no "one size fits all" strategy. Questions remain regarding the optimal sequence of treatments and the safe duration for deferring RC or PLND, underscoring the need for personalized care in this complex scenario. Ursula Vogl Petros Grivas Fabio Turco Dra. María Natalia Gandur Quiroga Emre Yekeduz Bárbara Melão Niklas Klümper Ignacio Duran Univ. Prof. Dr. Manuela Schmidinger Saeed Dabestani Geraldine PIGNOT Yüksel ÜRÜN Badrinath Konety Maria De Santis Renate Pichler Daniele Raggi Laura Mertens Daan De Maeseneer Verane Achard eva Comperat Peter Hoskin Cédric Lebâcle Laura Mertens Celena Scheede-Bergdahl Bernadett Szabados

Day One of #BLADDR24 Presenter: Dr. Ben-Max de Ruiter High-risk BCG-naive NMIBC: should we stick to BCG? The presentation on high-risk BCG-naive non-muscle invasive bladder cancer (NMIBC) discusses the ongoing role of BCG as the standard treatment, as no other treatment has demonstrated superiority over BCG in phase 3 trials. While gemcitabine-docetaxel has shown promise in retrospective data, new therapies are emerging but still await results from randomized comparative trials to establish their efficacy. Thus, despite the potential of alternative treatments, BCG remains the mainstay for high-risk BCG-naive NMIBC until further evidence becomes available. Ursula Vogl Petros Grivas Fabio Turco Dra. María Natalia Gandur Quiroga Emre Yekeduz Bárbara Melão Niklas Klümper Ignacio Duran Univ. Prof. Dr. Manuela Schmidinger Saeed Dabestani Geraldine PIGNOT Yüksel ÜRÜN Badrinath Konety Maria De Santis Renate Pichler Daniele Raggi Laura Mertens Daan De Maeseneer Verane Achard eva Comperat Peter Hoskin Cédric Lebâcle Laura Mertens Celena Scheede-Bergdahl Bernadett Szabados